Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine vs Desipramine in Chronic Pain
NCT03548454Phase 4
Key facts
- Status
- Completed
- Start
- Sep 2018
- Primary completion
- Dec 2023
- Countries
- 1
- Sponsor
- Stanford University
- Modality
- Small Molecules
- Conditions
- chronic pain
01
Overview
Phase 4, randomised, open-label trial in chronic pain comparing Duloxetine with Desipramine (2 arms). Primary endpoint: Pain Intensity at 6 months. Started Sep 2018; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Duloxetine
Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated.
Desipramine
Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated.
03
Who it enrols
Adult patients with persistent pain for more than 3 months who are candidates for antidepressant treatment. Patients with prior failure of duloxetine or desipramine are excluded.
04
Endpoints
Primary
Pain Intensity
Secondary
Physical Function
Pain Interference
Depression
Anxiety
Adherence
Beyond the preview
Go deeper on NCT03548454.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548454.